7.Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias，Syndax官网，2022 8.Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in ...
3.Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias,Syndax官网,2022 4.Update on a Phase 1/2 First-in-Human St...
Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias,Syndax官网,2022 on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed...
7.Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias,Syndax官网,2022 8.Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in ...
In a phase 1 first-inhuman clinical trial, the menin inhibitor revumenib, which is designed to disrupt the menin-MLL1 interaction, induced clinical responses in patients with leukaemia with KMT2Av or mutated NPM1 (ref.). Here we identified somatic mutations in MEN1 at the revumenib-men...
In a phase 1 first-in-human clinical trial, the menin inhibitor revumenib, which is designed to disrupt the menin–MLL1 interaction, induced clinical responses in patients with leukaemia with KMT2Ar or mutated NPM1 (ref. 6). Here we identified somatic mutations in MEN1 at the revumenib...
Revumenib (Revuforj), the first menin inhibitor to enter clinical trials, is leading the development pipeline, he states. Following closely are ziftomenib (KO-539), enzomenib (DSP-5336), and bleximenib (JNJ-75276617), according to Daver. Each of these agents is also being evaluated ...
2.Study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL with KMT2A/ MLL1r, NPM1 and other mutations. ClinicalTrials.gov. Updated October 26, 2022. Accessed November 1, 2022. https://c...
The COMET-001 study of a novel menin inhibitor is ongoing in relapsed or refractory AML. Can you discuss this study? The COMET-001 study is a first-in-human study of a different menin inhibitor, KO-539. This agent was initially evaluated in a dose escalation phase and then ...
In a phase 1 first-in-human clinical trial, the menin inhibitor revumenib, which is designed to disrupt the menin–MLL1 interaction, induced clinical responses in patients with leukaemia with KMT2Ar or mutated NPM1 (ref. 6). Here we identified somatic mutations in MEN1 at the revumenib...